Schechter M, Fischer M, Mosenzon O (2022) Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a narrative review and proposed clinical approach
Patients often ask for tirzepatide results by week, and while outcomes vary, common experiences include: Weeks 12: Reduced food noise, smaller portions, mild appetite suppression Weeks 36: Noticeable weight loss, looser clothing, improved energy Weeks 712: Fat loss becomes consistent, cravings decrease significantly Weeks 12+: Weight loss stabilizes into a predictable rhythm This gradual progression supports fat loss instead of muscle loss, helping avoid the rebound weight gain seen with crash diets
Active people & gym-goers looking for non-stimulant support around workouts and recovery
Activating both of these hormones improves glycemic control and promotes weight loss by enhancing insulin secretion, reducing glucagon secretion, slowing gastric emptying, and reducing appetite and food intake
Both medications may also be habit-forming
